Candesartan effect on inflammation in hypertension

• Published in: Hypertension research Vol. 33; no. 3; pp. 209 - 213
• Main Authors: Derosa, Giuseppe, Maffioli, Pamela, Salvadeo, Sibilla A T, Ferrari, Ilaria, Gravina, Alessia, Mereu, Roberto, Palumbo, Ilaria, D'Angelo, Angela, Cicero, Arrigo F G
• Format: Journal Article
• Language: English
• Published: England 01.03.2010
• Subjects: Aged; Antihypertensive Agents - pharmacology; Antihypertensive Agents - therapeutic use; Benzimidazoles - pharmacology; Benzimidazoles - therapeutic use; Biomarkers - blood; Blood Glucose - metabolism; Blood Pressure - drug effects; C-Reactive Protein - metabolism; Diabetes Mellitus, Type 2 - blood; Diabetes Mellitus, Type 2 - complications; Dietary Fats - adverse effects; Dietary Fats - pharmacology; Female; Humans; Hypertension - blood; Hypertension - drug therapy; Inflammation - blood; Inflammation - drug therapy; Inflammation - etiology; Insulin - blood; Intercellular Adhesion Molecule-1 - blood; Interleukin-6 - blood; Male; Middle Aged; Tetrazoles - pharmacology; Tetrazoles - therapeutic use; Triglycerides - blood
• ISSN: 0916-9636; 1348-4214
• DOI: 10.1038/hr.2009.212

The aim of this study was to evaluate the effect of candesartan on inflammatory biomarkers in hypertensive patients with and without type 2 diabetes mellitus after a standardized oral fat load (OFL). A total of 219 patients were enrolled: 106 patients were assigned to the non-diabetic hypertensive (NH) group, and 113 to the diabetic hypertensive (DH) group. All patients received candesartan therapy for 6 months and underwent a standardized OFL at baseline and after 6 months of therapy. We evaluated systolic blood pressure (SBP) and diastolic blood pressure (DBP), blood glucose (BG), triglycerides (Tg), soluble intercellular adhesion molecule-1 (sICAM-1), interleukin-6 (IL-6) and high-sensitivity C reactive protein (Hs-CRP). At baseline, glycated hemoglobin, homeostasis model assessment insulin resistance index, BG, fasting plasma insulin, Tg, sICAM-1, IL-6 and Hs-CRP in the DH group were significantly higher, whereas high-density lipoprotein-cholesterol value was significantly lower compared to NH group. After 6 months of candesartan therapy, sICAM-1, IL-6 and Hs-CRP were significantly lower compared to baseline in both groups; furthermore, there was a significant decrease of SBP and DBP values in both groups. After the OFL administered at baseline, there was an increase of Tg, sICAM-1, IL-6 and Hs-CRP in both groups. After the OFL administered after 6 months of therapy, instead, there was no significant variation of BG, Tg or sICAM-1 value in both groups, whereas there was an increase of IL-6 and Hs-CRP compared to time 0. We observed that candesartan treatment attenuated the inflammatory answer in both groups of patients, even if more efficiently in nondiabetic ones.